First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.

Elizabeth R. Plummer,Divyanshu Dua,Nicola Cresti,Aneta Suder,Yvette Drew,Peter Stephens,Marie Foegh,Steen Knudsen,Sharon McGonigle,Barbara Ink,Debashis Sarker

First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.

2018

Elizabeth R. Plummer
Divyanshu Dua
Nicola Cresti
Aneta Suder
Yvette Drew
Peter Stephens
Marie Foegh
Steen Knudsen
Sharon McGonigle
Barbara Ink
Debashis Sarker

2505Background: A phase I study was done to establish the safety, MTD and anti-tumour efficacy of the novel PARP 1/2 and Tankyrase 1/2 inhibitor, 2X-121 (E7449). A novel tumor agnostic molecular bi...

Keywords:

Poly ADP ribose polymerase
Cancer research
Pathology
Biomarker (medicine)
Messenger RNA
Medicine
in patient
first in human
drug response
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations